Status:
UNKNOWN
To Optimize the Therapeutic Pathway of Peginterferon Treatment in Patients With CHB Based on IFNA2p.Ala120Thr /ISGs.
Lead Sponsor:
Sun Yat-sen University
Collaborating Sponsors:
First People's Hospital of Foshan
Eighth Affiliated Hospital, Sun Yat-sen University
Conditions:
Hepatitis B
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
The study is to guide clinical cure of peginterferon alfa-2a treatment in patients with chronic hepatitis B based on the detection of interferon gene mutation (IFNA2p.Ala120Thr) and interferon-stimula...
Detailed Description
It is estimated that more than 400 million people are infected with hepatitis B virus (HBV) globally.How to make more patients with chronic hepatitis B get clinical treatment through the existing anti...
Eligibility Criteria
Inclusion
- Age between 18 and 60 years old;
- HBsAg positive, HBsAg quantification≤1500 IU/mL;
- Serum HBV DNA quantification \<100 IU/mL;
- HBeAg negative.
Exclusion
- Treated with interferon in the past six months;
- Liver cirrhosis or HCC and other associated tumors;
- Women during pregnancy or lactation;
- With liver disease caused by other causes;
- Combination infection of HIV or other immunodeficiency diseases;
- With diabetes, autoimmune diseases and other organ dysfunction or failure;
- Combination of other serious complications (infection, hepatic encephalopathy,gastrointestinal bleeding, hepatorenal syndrome, etc.);
- Others who cannot be treated with interferon;
- Anyone cannot return to the hospital for follow-up and follow-up visits regularly as planned
Key Trial Info
Start Date :
December 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2024
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT03771677
Start Date
December 1 2018
End Date
December 30 2024
Last Update
May 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chan Xie
Guangzhou, Guangdong, China, 510000